Prelude Therapeutics Q2 net loss $34.7M; cash $179.8M; clinical milestones for SMARCA2 and CDK9 programs

Prelude Therapeutics Inc

2024-Q2 EPS reported -$0.87

Net loss $34.7M ($0.46/share) vs $30.4M ($0.54/share) in Q2 2023; R&D expense rose to $29.5M from $25.0M.
Cash, equivalents and marketable securities $179.8M at June 30, 2024; runway extended into 2026.
PRT3789 interim Phase 1 data selected for oral presentation at ESMO Congress 2024 (Sept 13).
IND authorized for oral SMARCA2 degrader PRT7732; Phase 1 start expected H2 2024.
Clinical collaboration with Merck to evaluate PRT3789 in combination with KEYTRUDA; Phase 2 start expected Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.